PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Protocolos Clínicos e Diretrizes Terapêuticas 12 T ERMO DE ESCLARECIMENTO E RESPONSABILIDADE – TER É obrigatória a informação ao paciente ou a seu responsável legal dos potenciais riscos, benefícios e efeitos adversos relacionados ao uso do medicamento preconizado neste Protocolo, o que deverá ser formalizado por meio da assinatura de Termo de Esclarecimento e Responsabilidade. 13 R EFERÊNCIAS BIBLIOGRÁFICAS 1. Kieseier BC, Hartung HP. Therapeutic strategies in the Guillain-Barré syndrome. Semin Neurol. 2003;23(2):159-68. 2. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syndrome: an update. J Clin Neurosci. 2009;16(6):733-41. Epub 2009 Apr 7. 3. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326:1130-6. 4. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997;176 (Suppl 2):S92-8. 5. Hahn AF. Guillain-Barré syndrome. Lancet. 1998;352(9128):635-41. 6. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002;(2):CD001798. 7. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-66. 8. Hadden RD, Hughes RA. Management of inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2003:74(Suppl 2):9-14. 9. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7(10):939-50. 10. Hughes RA, Wijdicks EF, Benson E, Comblath DR, Hahn AF, Meythaler JM, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol. 2005;62(8):1194-8. 11. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21-4. 12. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997;349(9047):22530. 13. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meché FG. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology. 1999;53(3):598-604. 14. Romano JG, Rotta FT, Potter P, Rosenfeld V, Santibanez R, Rocha B, et al. Relapses in the Guillain- Barre syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve. 1998;21(10):1327-30. 15. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barré polyneuropathy. Brain.1984;107(Pt 1):21939. 16. Vucic S, Cairns KD, Black KR, Chong PS, Cros D. Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol. 2004;115(10):2329-35. 17. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol. 2001;58(6):913-7. 18. Olney RK, Aminoff MJ. Electrodiagnostic features of Guillain-Barré syndrome: the relative sensivity of different techniques Neurology. 1990;40(3 Pt 1):471-5. 19. Albers JW, Donofrio PD, McGonable TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1985;8(6):528-39. 20. Bradshaw DY, Jones HR Jr. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Musc Nerve. 1992;15(4):500-6. 21. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics. 2005;116 (1):8-14. 22. Miller RG, Peterson GW, Daube JR, Albers JW. Prognostic value of electrodiagnostic in Guillain-Barré syndrome. Muscle Nerve. 1988;11(7):769-74. 23. Yuki N, Yamada M, Sato S, Ohama E, Kawase Y, Ikuta F, et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve. 1993:16(6):642-7. 24. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol.1998;44(5):780-8. 25. Van der Meché FGA, Scmidtz PIM. A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillan-Barré Study Group. N Engl J Med.1992;326(17):1123-9. 26. Fross RD, Daube JR. Neuropathy in the Miller-Fischer syndrome: clinical and electrophysiologic findings. Neurology. 1987;37(9):1493-8. 27. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome Neurology. 2001;56(8):1104-6. 28. Blau I, Casson I, Lieberman A,Weiss E. The not-so-benign Miller Fisher syndrome: 552